Megaphone icon ETF Database is now VettaFi. Read More >
ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • Entrepreneur ETF
    • Equity ETF
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Future ETFs
    • Gold & Silver Investing
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Modern Alpha
    • Multi-Asset
    • Multi-Factor
    • Portfolio Strategies
    • Retirement Income
    • Smart Beta
    • Thematic Investing
    • Volatility Resource
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Videos & Podcasts
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Disruptive Technology Channel
  2. Some ARKG Components Might Lead in Genetic Testing
Disruptive Technology Channel
Share

Some ARKG Components Might Lead in Genetic Testing

Tom LydonJun 01, 2022
2022-06-01

In the healthcare space, it’s often said that an ounce of prevention is worth a pound of cure, and that’s undeniably true when it comes to cancer prevention and treatment.

A clear avenue for bolstering cancer patient outcomes and potentially improving preventative measure is through enhanced genetics-based testing. Some exchange traded funds, including the ARK Genomic Revolution Multi-Sector Fund (ARKG ), have exposure to the growing hereditary testing arena.

Interestingly, there are significant growth opportunities for hereditary testing providers because the current cancer testing landscape as it pertains to hereditary testing revolves around a limited number of cancers.

“Despite mounting evidence from Myriad Genetics (MYGN), Invitae (NVTA), and other genetic testing leaders suggesting that patients with many cancer types could benefit, hereditary testing today is focused primarily on breast and ovarian cancers,” according to ARK Investment Management research.

For now, Invitae is a small part of the ARKG roster, while Myriad Genetics isn’t part of the lineup. However, it’s worth remembering that ARKG, unlike many of its genomic ETF brethren, is actively managed. That means the ARK ETF can be more responsive to emerging genetics trends, including cancer screening, than index-based rivals.

Indeed, data confirm the validity of expanding the field of cancers that be identified early by way of hereditary screening. The earlier cancer is found, the better patient outcomes are.

“As examples, 17%, or 1 in 6 patients, with prostate, colorectal, pancreatic, or dermatological cancers have hereditary cancer mutations that are clinically actionable,” added ARK. “Invitae has shown that pancreatic cancer (PDAC) patients with certain hereditary variants respond better than others to chemotherapy, suggesting that testing would have prognostic utility. A Myriad study showed that, for certain mutations, an increase in a measurement of risk, the odds ratio (OR), could help oncologists tailor cancer surveillance strategies.”

One thing for investors to remember is that boosting genetic testing is very much a long-term ballgame, which is to say, don’t expect it to lift ARKG’s fortunes overnight because more education is needed, among other factors.

“While universal hereditary genetic testing could provide prognostic, diagnostic, and therapeutic information to cancer patients, the barriers to adoption today still are significant: a shortage of genetic counselors, a lack of education for physicians and patients, and restrictive medical guidelines. With lower costs and increasing evidence of clinical utility, we believe that current policies will change, ultimately increasing the demand for hereditary testing,” concluded ARK.

For more news, information, and strategy, visit our Disruptive Technology Channel.

Loading Articles...
Help & Info
  • Contact Us
  • Mission Statement
  • Press
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © ETF Flows LLC
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X